SREBF1 and non-small cell lung carcinoma: Long-term exposure to cisplatin develops chemoresistance, desensitizes non-small cell lung carcinoma (NSCLC) cells, and enhances SREBP1-mediated adipogenesis, affecting cancer prognosis.